Stock Market Reviews

Read and share opinions on BMY (Bristol-Myers Squibb Company) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Goldman Sachs Raises Bristol-Myers (BMY) Target, Keeps Neutral Rating
  Dec 30, 2025
• What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)?
  Dec 30, 2025
• Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound?
  Dec 24, 2025
• Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact
  Dec 23, 2025
• Will the Recent Pricing Deal With the Government Impact BMY's Sales?
  Dec 23, 2025
• FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma
  Dec 21, 2025

BMY News

• What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)?
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the best affordable healthcare stocks to buy now. On December 22, Bristol-Myers Squibb Company (NYSE:BMY) received a Buy rating from Guggenheim with a price target of $62.00. In a separate development, Bristol-Myers Squibb Company (NYSE:BMY) announced on December 19 an agreement with the United States government for the provision of […]
  Dec 30, 2025
• 3 Drug Stocks to Buy at a Discount
  The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.
  Dec 27, 2025
• This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year
  Bristol Myers Squibb could become the pharmaceutical industry’s turnaround story for 2026. Shares are off 9% in 2025 after a series of drug pipeline disappointments, while major patent expirations, like one for cancer drug Revlimid, could cause earnings to fall 5% in 2026 and another 5% in 2027. At the current price, investors are paying little for Bristol Myers’ pipeline, led by Cobenfy, a schizophrenia drug being tested as a treatment for psychosis among Alzheimer’s patients, and Milvexian, a treatment of atrial fibrillation and strokes.
  Dec 27, 2025
• Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound?
  Bristol-Myers Squibb (BMY) has quietly staged a comeback, with the stock up about 17% over the past month and roughly 23% in the past 3 months, catching the attention of value focused investors. See our latest analysis for Bristol-Myers Squibb. That rebound sits against a more muted backdrop, with the share price still showing a slightly negative year to date return and a modest 1 year total shareholder return. This suggests sentiment has only recently started to improve as investors reassess...
  Dec 24, 2025
• Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
  AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
  Dec 24, 2025
• Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
  The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
  Dec 24, 2025
• Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever
  If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.
  Dec 24, 2025
• Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
  Dec 23, 2025
• Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact
  Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Several of the largest US and European drugmakers struck agreements with President Donald Trump on December 19 to voluntarily lower the prices of certain medicines. The move comes as the administration pushes to tie US drug prices more closely to […]
  Dec 23, 2025
• Will the Recent Pricing Deal With the Government Impact BMY's Sales?
  BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
  Dec 23, 2025
• Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
  Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
  Dec 22, 2025
• Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends
  XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.
  Dec 22, 2025
• Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
  CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.
  Dec 22, 2025
• Radiopharmaceutical specialist Aktis seeks an IPO
  The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.
  Dec 22, 2025
• FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, while maintaining a Neutral rating on the shares. Earlier on December 4, Bristol-Myers Squibb announced that the US FDA approved Breyanzi (lisocabtagene […]
  Dec 21, 2025
• BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 15, BofA upgraded the company’s stock to “Buy” from “Neutral” with a price objective of $61, an increase from $52, given the company’s R&D pipeline, as reported by The Fly. As per the firm, 4-6 programs are expected […]
  Dec 21, 2025
• Cytokinetics set to battle Bristol Myers as FDA approves heart drug
  The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which is on its way to topping $1 billion in sales this year.
  Dec 21, 2025
• Great week for Bristol-Myers Squibb Company (NYSE:BMY) institutional investors after losing 0.8% over the previous year
  Key Insights Institutions' substantial holdings in Bristol-Myers Squibb implies that they have significant influence...
  Dec 20, 2025
• I’ll Play, Says Jim Cramer About Bristol-Myers (BMY)
  We recently published 12 Stocks on Jim Cramer’s Radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks aon Jim Cramer’s radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. The firm has seen some attention from analysts in December. For instance, Jefferies reiterated a Buy rating and a $68 […]
  Dec 19, 2025
• Trump reaches deal with 9 drug companies to lower prices
  President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
  Dec 19, 2025
• Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
  Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
  Dec 19, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t
  Dec 19, 2025
• Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals
  All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige
  Dec 19, 2025
• Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
  Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.
  Dec 19, 2025
• Nine Drugmakers Strike Deals With Trump, With More to Come
  The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.
  Dec 19, 2025
• Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases
  The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano
  Dec 19, 2025
• Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
  PRINCETON, N.J., December 19, 2025--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
  Dec 19, 2025
• Can Merck Successfully Steer Through the Upcoming Headwinds?
  MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.
  Dec 19, 2025
• Cytokinetics Wins FDA Approval For Its First Drug, Taking On Bristol Myers
  Cytokinetics won its first Food and Drug Administration approval late Friday, leading shares to jump in after-hours action.
  Dec 19, 2025
• Nine Big Drugmakers Reach Pricing Deals With White House
  Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower. Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.
  Dec 19, 2025
• Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
  Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
  Dec 19, 2025
• No, Elon Musk Did Not Buy This Penthouse. It’s Up for Sale.
  The estate of late beauty mogul Sydell Miller’s is now listing the roughly 20,000-square-foot unit for $78.9 million, ending rumors the tech billionaire bought it late last year.
  Dec 19, 2025
• More Drugmakers Reach Deals With White House to Lower Prices
  The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
  Dec 19, 2025
• White House Cuts Drug-Pricing Deals With Pharma Companies, Tilting System Toward Self-Pay
  The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.
  Dec 19, 2025
• 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
  The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
  Dec 18, 2025
• Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
  PRINCETON, N.J., December 18, 2025--Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
  Dec 18, 2025
• Harbour BioMed and BMS sign multi-specific antibody collab
  Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.
  Dec 17, 2025
• Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
  Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
  Dec 17, 2025
• Guggenheim Sets $62 Target on Bristol-Myers Squibb Company (BMY) After FDA Priority Review
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company is one of the most undervalued stocks on our list. On Friday, December 12, 2025, TheFly reported that Guggenheim upgraded BMY’s stock rating from Neutral to Buy and set a new price target of $62, reflecting growing […]
  Dec 17, 2025
• These 2 Healthcare Stocks Just Declared Dividend Raises
  The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.
  Dec 17, 2025
• Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
  Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.
  Dec 17, 2025
• BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
  BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
  Dec 15, 2025
• US Equity Markets End Lower as Technology Sector Continues to Drag Down Broader Market
  US equity indexes closed lower Monday as technology stocks continued to face pressure following last
  Dec 15, 2025
• Why Bristol-Myers Squibb (BMY) Stock Is Up Today
  Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its price target.
  Dec 15, 2025
• Sector Update: Health Care Stocks Gain Late Afternoon
  Health care stocks rose late Monday afternoon with the NYSE Health Care Index gaining 1.2% and the S
  Dec 15, 2025
• Mars buys Kellanova, Goldman Sachs makes bullish hotel calls
  Market Domination host Josh Lipton outlines the stories driving interest in some of Monday's trending tickers, including Mars Snacking's acquisition of Kellanova (K); Bank of America's upgrade of Bristol Myers (BMY); and Goldman Sachs's bullish calls on Marriott (MAR), Hilton (HLT), and Las Vegas Sands (LVS). To watch more expert insights and analysis on the latest market action, check out more Market Domination.
  Dec 15, 2025
• How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum
  In recent days, Bristol Myers Squibb’s board approved a 1.6% increase in its quarterly common dividend to US$0.63 per share for February 2026 and reaffirmed its preferred dividend, while the company also secured FDA Priority Review for an Opdivo label expansion in advanced classical Hodgkin lymphoma and new approval for Breyanzi in relapsed or refractory marginal zone lymphoma. Together with extensive hematology data at the ASH meeting and progress in AI-enabled drug discovery...
  Dec 15, 2025
• Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says
  Bristol-Myers Squibb (BMY) offers a favorable risk/reward heading into 2026, supported by four to si
  Dec 15, 2025
• Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More
  Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began a big rotation last week out of the AI stocks that have led the market higher since ChatGPT was introduced over three years ... Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More
  Dec 15, 2025
• 2 Dividend Stocks to Double Up on Right Now
  These dividend growth machines could have considerable upside for long-term investors.
  Dec 14, 2025
• The Smartest Dividend Stocks to Buy With $1,000 Right Now
  Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses.
  Dec 13, 2025
• Why Bristol-Myers Squibb (BMY) Stock Is Up Today
  Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from "Neutral" to "Buy" and set a new price target of $62.
  Dec 12, 2025
• 3 Top Dividend Stocks to Maximize Your Retirement Income
  The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
  Dec 12, 2025
• Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
  Bristol Myers Squibb (BMY) closed the most recent trading day at $52.41, moving +2.36% from the previous trading session.
  Dec 12, 2025
• Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
  Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
  Dec 12, 2025
• Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
  BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
  Dec 12, 2025
• Is Bristol-Myers Squibb a Value Opportunity After 5.1% Rebound and DCF Outlook?
  If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you are in the right place to unpack what the current share price is really telling us. The stock has edged up about 5.1% over the last month after a softer year to date, with the price still down 9.8% since January and around 4.5% lower over the past year. This suggests sentiment is shifting but not yet fully recovered. Recently, investors have been focused on...
  Dec 12, 2025
• Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls
  Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls
  Dec 12, 2025
• How the Narrative Surrounding Bristol Myers Squibb Is Shifting After Recent Sector and Policy Updates
  Bristol-Myers Squibb has seen its fair value estimate nudged slightly higher to about $53.55 per share, even as analysts bake in a marginally higher discount rate of roughly 6.96% and a deeper projected revenue decline of around -5.34%. This combination reflects cautious recognition that sector wide underperformance and a potentially less punitive policy backdrop could support a gradual rerating, even while expectations for top line growth remain subdued. Stay tuned to see how investors can...
  Dec 12, 2025
• The Best Turnaround Stock to Invest $1,000 in Right Now
  Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.
  Dec 12, 2025
• Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak
  Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.
  Dec 12, 2025
• Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More
  Pre-Market Stock Futures: The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything. The Federal Reserve, as expected, cut rates again and indicated that another cut could come in 2026. Oracle Corp. (NASDAQ: ORCL), which has been on fire this ... Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More
  Dec 12, 2025
• U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
  PRINCETON, N.J., December 11, 2025--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma
  Dec 11, 2025
• Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
  The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.
  Dec 11, 2025
• Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035
  The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting children and aggressive in adults, ALL is increasingly treated with personalized medications like Tyrosine Kinase Inhibitors and CAR-T cell therapy, transforming patient outcomes. Despite challenges like high treatment costs and drug resistance, the demand for innovative combination therapies is risin
  Dec 11, 2025
• 3 Unpopular Stocks with Questionable Fundamentals
  Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
  Dec 11, 2025
• Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound
  Bristol-Myers Squibb (BMY) has been quietly rebuilding momentum, with the stock up around 8% over the past month even as its one year return remains slightly negative. That disconnect is drawing fresh investor attention. See our latest analysis for Bristol-Myers Squibb. That recent 30 day share price return of about 8% contrasts with a negative year to date move and an 8.5% decline in one year total shareholder return, suggesting early but improving momentum as investors reassess risk and...
  Dec 10, 2025
• Bristol Myers Squibb Announces Dividend Increase
  PRINCETON, N.J., December 10, 2025--Bristol Myers Squibb Announces Dividend Increase
  Dec 10, 2025
• Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY)
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in. On December 4, Jefferies reiterated a Buy rating on Bristol-Myers Squibb Company (NYSE:BMY) with a price target of $68. The same day, Scotiabank lifted the price target on Bristol-Myers Squibb Company (NYSE:BMY) to $53 from $45 while maintaining a Sector Perform rating […]
  Dec 10, 2025
• 2 Pharmaceutical Stocks to Buy at a Discount
  Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.
  Dec 10, 2025
• 1 Large-Cap Stock on Our Buy List and 2 We Turn Down
  Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
  Dec 9, 2025
• Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
  Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
  Dec 9, 2025
• Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
  Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
  Dec 9, 2025
• BioNTech, Bristol Myers Report Early Breast Cancer Tumor Response Data for Experimental Antibody Treatment
  BioNTech (BNTX) said Tuesday it and Bristol Myers Squibb (BMY) reported interim phase 2 data showing
  Dec 9, 2025
• Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb
  The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a
  Dec 9, 2025
• BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
  Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levelsData highlight the potential of pumitamig for patients wit
  Dec 9, 2025
• Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer
  MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).
  Dec 9, 2025
• Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
  Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
  Dec 8, 2025
• Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
  PRINCETON, N.J., December 08, 2025--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
  Dec 8, 2025
• Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment
  Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. […]
  Dec 8, 2025
• Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]
  Dec 6, 2025
• Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
  Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
  Dec 5, 2025
• Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
  PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
  Dec 5, 2025
• Do These 3 Healthcare Stocks Need a Checkup?
  These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?
  Dec 5, 2025
• Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use
  Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.
  Dec 5, 2025
• 3 Stocks Under $50 We’re Skeptical Of
  Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
  Dec 4, 2025
• BMY Gains on News of Continuation of Alzheimer's Disease Study
  Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
  Dec 4, 2025
• Tigerlily Foundation Launches the "Bliss Collective: Brunch & Sip" Series to Empower, Educate, and Uplift Women Nationwide
  The Tigerlily Foundation (Tigerlily) proudly announces the launch of the Bliss Collective: Brunch & Sip, a new national event series designed to empower women, build community, and amplify awareness of health equity and clinical trial participation through culturally relevant lifestyle experiences. This powerful initiative is being launched in partnership with Bristol Myers Squibb.
  Dec 4, 2025
• C3 AI Announces Fiscal Second Quarter 2026 Results
  REDWOOD CITY, Calif., December 03, 2025--C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced financial results for its fiscal second quarter ended October 31, 2025.
  Dec 3, 2025
• Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
  Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
  Dec 3, 2025
• Sector Update: Health Care Stocks Higher Wednesday Afternoon
  Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel
  Dec 3, 2025
• Sector Update: Health Care Stocks Higher Late Afternoon
  Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He
  Dec 3, 2025
• Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?
  Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025
• Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
  LOS ANGELES, December 03, 2025--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb
  Dec 3, 2025
• Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates
  Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data, according to the firm, offers “tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis,” which bolsters trust in BMY’S […]
  Dec 3, 2025
• Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
  PRINCETON, N.J., December 03, 2025--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
  Dec 3, 2025
• Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock
  Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.
  Dec 3, 2025
• Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.
  The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.
  Dec 3, 2025
• Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update
  Bristol-Myers Squibb shares rallied 5.6% Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment. Analysts said investors were relieved that the news wasn’t worse, as there had been some fear that Bristol-Myers would disclose by the end of this month that the study failed outright. The study is testing Bristol-Myers’ Cobenfy schizophrenia drug as a treatment for psychosis in Alzheimer’s disease patients.
  Dec 3, 2025
• After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis
  Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.
  Dec 3, 2025
• Sector Update: Health Care Stocks Lower Tuesday Afternoon
  Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 0.5% and the Hea
  Dec 2, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index and the Health C
  Dec 2, 2025
• Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
  Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
  Dec 2, 2025
• Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
  Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, M
  Dec 2, 2025
• BioNTech (BNTX) Is Up 7.9% After Raising 2025 Revenue Guidance on Bristol-Myers Collaboration
  In late November, BioNTech raised its full-year 2025 revenue guidance, recognizing US$700 million from its collaboration with Bristol-Myers Squibb, while reporting a net loss for the quarter due to a contractual dispute and continuing investments to transition into a commercial oncology company. An important development from this period is BioNTech’s accelerated clinical advancement, highlighted by ongoing Phase III trials in lung and triple-negative breast cancers and the outlined timeline...
  Dec 1, 2025
• Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
  PRINCETON, N.J., December 01, 2025--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio
  Dec 1, 2025
• Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
  The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
  Dec 1, 2025
• Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
  SOUTH SAN FRANCISCO, Calif., December 01, 2025--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad’s app
  Dec 1, 2025
• 2 Undervalued, High-Quality Companies to Buy Now and Hold Forever
  If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.
  Dec 1, 2025
• BMY Gains Attention as Bayer Reports FXIa Trial Success
  Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Boring Dividend Stocks to Buy. Bayer repor⁠t​ed positive Phase‌ 3 result⁠s for its FXIa inhi‍bitor as​undexian, h‌itting key efficacy an‍d safety targets and dr‌awing renewed attention to the broader FXIa drug class. Morg​a⁠n Stanley noted this could increase interest i‌n s⁠imilar treatments from Bristol-Myers Squibb […]
  Nov 30, 2025
• 2 Top Dividend Stocks to Buy and Hold
  Patience will be rewarded for those who stick with these two healthcare stocks.
  Nov 30, 2025
• Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend?
  The pharma stock yields more than 4x the S&P 500 average.
  Nov 29, 2025
• Bristol Myers (BMY) Gains EU Approval for Breyanzi in Mantle Cell Lymphoma—What Does This Mean?
  Earlier this week, Bristol Myers Squibb announced that the European Commission approved its CAR-T cell therapy Breyanzi for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic treatments, including a Bruton’s tyrosine kinase inhibitor. This expanded approval, based on positive trial data, further establishes Breyanzi as a key asset in the company’s oncology portfolio, opening up access for eligible patients across the EU and EEA countries. We’ll now...
  Nov 28, 2025
• Bristol-Myers Squibb Surges 15% After Drug Approvals: Is the Stock a Bargain in 2025?
  Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with confidence. After a rocky start to the year, Bristol-Myers Squibb has staged an impressive rebound, gaining 15.6% in the last month and 6.5% in just the past week. However, it is still down 13.3% year-to-date. Investor sentiment has been shaped by headlines ranging from major drug approvals to strategic partnerships, which have fueled recent optimism about...
  Nov 28, 2025
• Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
  GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
  Nov 28, 2025
• Is Bristol-Myers Stock Underperforming the S&P 500?
  Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.
  Nov 28, 2025
• BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)
  Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
  Nov 27, 2025
• Bristol-Myers Squibb Company (BMY): A Bull Case Theory
  We came across a bullish thesis on Bristol-Myers Squibb Company on CompoundingLab’s Substack. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $49 recently. BMY’s trailing and forward P/E were 16.6 and 8 respectively according to Yahoo Finance. Bristol-Myers Squibb Co. (NYSE: BMY) appears modestly undervalued following its recent […]
  Nov 27, 2025
• Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
  Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
  Nov 27, 2025
• Follicular Lymphoma Market Trends, Opportunities, Growth Challenges and Competitive Intelligence 2025-2035
  The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents challenges like relapse and treatment resistance, underscoring the need for novel treatment strategies. Innovative therapies such as monoclonal antibodies and CAR T-cell therapies are enhancing patient outcomes by providing more precise and less toxic options compared to traditional chemotherapy. Ke
  Nov 27, 2025
• Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
  PRINCETON, N.J., November 26, 2025--Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
  Nov 26, 2025
• Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices
  The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,
  Nov 26, 2025
• BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
  Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
  Nov 25, 2025
• A Fresh Look at Bristol-Myers Squibb (BMY) Valuation After Recent Share Price Rebound
  Bristol-Myers Squibb (BMY) shares have seen mixed movement over the past month, with the stock rebounding nearly 9% but still trading below this year’s highs. Investors continue to monitor the company’s performance trends and financials. See our latest analysis for Bristol-Myers Squibb. Even after this month’s strong 8.9% share price return, Bristol-Myers Squibb is still trying to regain its footing following a tough year for total shareholders, who are down nearly 15%. While short-term...
  Nov 25, 2025
• Bayer Resurrects Scrapped Blood-Thinning Drug as Breakthrough Stroke Treatment
  The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.
  Nov 25, 2025
• PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know
  A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers, making them crucial for insurers focused on the
  Nov 24, 2025
• Bristol Myers Squibb to Host Hematology-Focused Investor Event
  PRINCETON, N.J., November 24, 2025--Bristol Myers Squibb to Host Hematology-Focused Investor Event
  Nov 24, 2025
• Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
  PRINCETON, N.J., November 24, 2025--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
  Nov 24, 2025
• Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer
  Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.
  Nov 24, 2025
• Investors bet on newer technology and indications for CGTs
  The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.
  Nov 24, 2025
• Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?
  Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
  Nov 23, 2025
• PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
  Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
  Nov 21, 2025
• This Medical Technology Leader Sees Profit Growth Topping 44%
  The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.
  Nov 21, 2025
• Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.
  Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.
  Nov 21, 2025
• Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
  BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
  Nov 20, 2025
• Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance
  Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]
  Nov 20, 2025
• This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
  For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.
  Nov 20, 2025
• The Tech Rotation Is On and Dividend-Paying Blue-Chips Are the Winners
  These six top blue-chip dividend stocks remain outstanding ideas for investors seeking to move away from tech stocks.
  Nov 20, 2025
• Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
  Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
  Nov 19, 2025
• Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman
  MONTREAL, November 19, 2025--Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more effective immunotherapies, announces the appointment of Dr. John Burke and Dr. Alan Korman to its Scientific Advisory Board.
  Nov 19, 2025
• Why GRAIL Stock Could Be Biotech’s Next Big Breakout
  Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.
  Nov 19, 2025
• [Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
  [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.
  Nov 18, 2025
• Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
  PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
  Nov 18, 2025
• Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3
  Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.
  Nov 18, 2025
• Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
  PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
  Nov 18, 2025
• Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation
  Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by gradual scarring, limiting lung function. The exact cause is unknown, but it combines genetic and environmental factors. With symptoms like shortness of breath and fatigue, IPF lacks a cure, necessitating effective treatments. Increasing cases, driven by aging populations and better diagnosis, spur R&D on new therapies. Companies like Hoffmann-La Roche and Bristol-Myers Squibb innovate with targeted and biologic therapie
  Nov 18, 2025
• 1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
  A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
  Nov 17, 2025
• BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
  BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
  Nov 17, 2025
• Stocks Set for Muted Open as Investors Await Nvidia Earnings and U.S. Jobs Data
  December S&P 500 E-Mini futures (ESZ25) are up +0.02%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.09% this morning, pointing to a muted open on Wall Street as cautious sentiment prevailed at the start of a busy week.
  Nov 17, 2025
• Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target
  Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 13, Scotiabank bega‍n cove‌rage o⁠f Bristol-Myers Squibb Company (NYSE:BMY) with a Sect⁠or Perform rat‍ing and s⁠et a price targ‍et of $4‌5, as reported by The Fly. ‍In the third quart⁠er of 2025, Bristol-Myers Squibb Company (NYSE:BMY) […]
  Nov 16, 2025
• 3 Reasons to Avoid BMY and 1 Stock to Buy Instead
  While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their next move.
  Nov 14, 2025
• Update on Phase 3 Librexia ACS Trial
  PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial
  Nov 14, 2025
• US Equity Indexes Mixed Amid Technology Rebound
  US equity indexes were mixed ahead of Friday's close amid selective dip-buying in technology and inf
  Nov 14, 2025
• Sector Update: Health Care Stocks Ease Late Afternoon
  Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea
  Nov 14, 2025
• US Equity Indexes Mixed in Midday Trading
  US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec
  Nov 14, 2025
• Sector Update: Health Care Stocks Decline Premarket Friday
  Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL
  Nov 14, 2025
• US Equity Indexes Mixed as Technology Rebound Helps Lift Nasdaq, S&P 500
  US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec
  Nov 14, 2025
• Virgin Galactic misses on Q3 revenue, Bristol Myers halts drug trial
  Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Virgin Galactic (SPCE) shares rising while missing third quarter revenue estimates and narrowing its net losses below forecasts, Applied Materials (AMAT) forecasting a drop in chip equipment sales, and Bristol Myers Squibb (BMY) halting its trial for a blood clot drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
  Nov 14, 2025
• Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
  Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
  Nov 14, 2025
• Major Financing and Expanded SCRI Partnership Might Change the Case for Investing in Bristol-Myers Squibb (BMY)
  Bristol Myers Squibb completed a €5 billion senior unsecured note offering and announced an expanded collaboration with Sarah Cannon Research Institute to accelerate development and access to innovative cancer therapies by streamlining clinical trial delivery across more than 200 U.S. locations. This combination of large-scale financing and partnership expansion positions the company to enhance its oncology pipeline while improving financial flexibility for future initiatives. We'll explore...
  Nov 14, 2025
• Top Stock Movers Now: StubHub, DoorDash, Netflix, and More
  Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.
  Nov 14, 2025
• Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail
  Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.
  Nov 14, 2025
• Bristol Myers Shares Sink on Yet Another Trial Failure
  Bristol said it had decided to stop one of its ongoing Phase 3 trials testing an experimental blood thinner called milvexian.
  Nov 14, 2025
• S&P 500 Gains and Losses Today: DoorDash Drives Higher on a New Partnership; Bristol-Myers Squibb Stock Falls
  A delivery company got a boost from a new partnership announcement on Friday, Nov. 14, 2025, while the termination of a clinical trial weighed on a pharmaceutical firm.
  Nov 14, 2025
• Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
  Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
  Nov 13, 2025
• BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
  Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
  Nov 13, 2025
• Top Research Reports for NVIDIA, Micron Technology & Thermo Fisher
  NVIDIA, Micron Technology and Thermo Fisher lead today's top analyst picks, each showing strong growth trends and strategic advances.
  Nov 13, 2025

BMY Reviews

• StonkViking

  Dec 30, 2025

  $BMY They’re in the healthcare hustle, making serious moves for the win.

  Buy

• PortfolioFreak

  Dec 29, 2025

  $BMY Pharma is a battlefield! Drug approvals, patent cliffs, and regulatory hurdles are constant threats. Will this company rise above the chaos or succumb to the pressures of the industry?

  Buy

• AlgoAce

  Dec 29, 2025

  $BMY With their meds, feeling better is a breeze! If only they could apply that magic to homework too.

  Buy

• IndexPredator

  Dec 29, 2025

  $BMY With the biotech battlefield getting intense, can they defend their territory effectively? It feels like a fight for survival every quarter!

  Sell

• RiskAssassin

  Dec 28, 2025

  $BMY With groundbreaking treatments in the pipeline, the excitement is electric! But will they meet expectations, or will the hype fizzle out?

  Buy

• AlphaRogue

  Dec 27, 2025

  $BMY With more life-saving drugs than a superhero movie, this company is basically the Avengers of pharma. Watch out, bad guys!

  Buy

• DiamondHands

  Dec 26, 2025

  $BMY This stock is like your favorite superhero—always swooping in to save the day when you need it most!

  Buy

• ProfitGremlin

  Dec 26, 2025

  $BMY Big pharma flexing, making moves to keep us all healthy!

  Buy

• YieldVector

  Dec 26, 2025

  $BMY In the pharmaceuticals arena, stakes are high and competition is fierce. Will the latest pipeline creations soar to new heights or crash under pressure? The anxiety is real!

  Sell

• ProfitLancer

  Dec 26, 2025

  $BMY Finding growth with this company feels like chasing shadows.

  Sell

• RiskRaider

  Dec 25, 2025

  $BMY Big pharma's got more skeletons than cures.

  Sell

• TradeHex

  Dec 25, 2025

  $BMY With a commitment to research and extensive pipeline of products, this organization stands out in the pharmaceutical industry, indicating a promising trajectory in addressing healthcare needs.

  Buy

• QuantQuest

  Dec 25, 2025

  $BMY This stock is like the superhero of the pharma world – saving us from all kinds of ailments, cape not included!

  Buy

• MarketReaper

  Dec 25, 2025

  $BMY Like a vintage video game, this stock has some serious nostalgia vibes—might just be a classic worth holding onto!

  Buy

• OptionNomad

  Dec 25, 2025

  $BMY With the ever-looming patent cliffs and intense competition from generics, the pressure mounts. Every quarter brings a nail-biting cliffhanger on trial results. How will they cope with these relentless challenges?

  Sell

• CapitalHex

  Dec 25, 2025

  $BMY Renowned for its commitment to research and innovation in the pharmaceutical industry, this company continues to develop groundbreaking treatments that positively impact patient outcomes.

  Buy

• BullishShade

  Dec 25, 2025

  $BMY This company is at the forefront of innovation in the pharmaceutical industry, focusing on groundbreaking therapies that address critical health issues. Their commitment to research and development positions them strongly for long-term growth in a competitive market.

  Buy

• TheEarningsBeast

  Dec 25, 2025

  $BMY Creating drugs that tackle serious stuff? They probably have a superhero cape hidden somewhere in the lab!

  Buy

• StockNova

  Dec 24, 2025

  $BMY With a robust pipeline and a history of impactful therapies, this organization continues to demonstrate resilience and adaptability. Their strategic initiatives indicate a strong potential for sustainable growth in the competitive pharmaceutical landscape.

  Buy

• GainMachine

  Dec 24, 2025

  $BMY They’re like the wizards of medicine, conjuring up cures while we just sit back and enjoy the show!

  Buy

• PortfolioFreak

  Dec 24, 2025

  $BMY With ongoing trials and market pressures, the waiting game is intense! The potential for breakthroughs exists, but so does the threat of disappointing news. Can they withstand the turmoil?

  Buy

• EarningsSync

  Dec 24, 2025

  $BMY With a robust pipeline, will this giant continue to lead or face unforeseen challenges? The anticipation is palpable as we wonder what's next for them!

  Buy

• TendieTitan

  Dec 24, 2025

  $BMY This one’s like your favorite grandparent; always around to help when you need a little comfort!

  Buy

• GainMachine

  Dec 23, 2025

  $BMY This company’s got the cure for a boring day! Who needs Netflix when you can binge on life-saving meds?

  Buy

• FiscalRiot

  Dec 23, 2025

  $BMY In the high-stakes world of pharmaceuticals, every breakthrough can feel like a lottery ticket—will the jackpot come through or will it be another disappointment?

  Buy

• StonkDestroyer

  Dec 23, 2025

  $BMY Just another pharma hoping for a miracle drug.

  Sell

• StockShotz

  Dec 22, 2025

  $BMY This giant is like the dependable friend who always brings snacks to the party—everyone loves them!

  Buy

• BullBrawler

  Dec 21, 2025

  $BMY Still waiting for this pharmaceutical miracle to happen.

  Sell

• BearHunter

  Dec 21, 2025

  $BMY This stock is like a superhero in a lab coat, saving the day with meds while making the stock market feel a bit healthier!

  Buy

• VolatilityNomad

  Dec 21, 2025

  $BMY This pharmaceutical giant is more about hype than help lately.

  Sell

• CashClown

  Dec 21, 2025

  $BMY In the health game, bringing the goods to keep us feeling good!

  Buy

• TraderFury

  Dec 20, 2025

  $BMY With breakthroughs in pharmaceuticals potentially on the table, this stock could change the game entirely or face setbacks that leave investors reeling. The tension is palpable!

  Buy

• BullRaid

  Dec 20, 2025

  $BMY A pharmaceutical giant trying to look like a savior. Spoiler alert: it’s not.

  Sell

• AlphaVandal

  Dec 20, 2025

  $BMY Pharma companies are like leeches; they suck your wallet dry.

  Sell

• FUDCrusher

  Dec 19, 2025

  $BMY Big moves in the game, gotta watch this player for real!

  Buy

• StockStrider

  Dec 19, 2025

  $BMY As a leader in pharmaceuticals, this organization is dedicated to advancing healthcare solutions. Their ongoing pipeline of innovative therapies reflects a commitment to improving patient outcomes.

  Buy

• CapitalFrame

  Dec 18, 2025

  $BMY This established pharmaceutical giant continues to deliver innovative therapies that address significant healthcare needs. Its robust pipeline and strategic partnerships enhance its potential for future advancements.

  Buy

• QuantAssault

  Dec 17, 2025

  $BMY This one's like grandma's secret recipe—old school, trustable, and packed with timeless goodness!

  Buy

• MarketDrift

  Dec 17, 2025

  $BMY This one’s got the serious meds; they're dishing out health like it's candy!

  Buy

• DiamondHands

  Dec 16, 2025

  $BMY This company is the dependable friend who always has your back during a group project—can’t imagine life without them!

  Buy

• FinTechFrost

  Dec 15, 2025

  $BMY This company is like the favorite teacher everyone loves—always giving out good grades and wisdom, but watch out for the surprise quizzes!

  Buy

• MarketRender

  Dec 15, 2025

  $BMY As new treatments flood the market, this pharmaceutical powerhouse must innovate or risk being left behind in the race for breakthroughs. The pressure is immense!

  Buy

• TheRiskDealer

  Dec 15, 2025

  $BMY Sentiment improving across the board.

  Buy

• GainSurge

  Dec 14, 2025

  $BMY With a solid pipeline and strategic moves, this giant feels like it’s on the brink of a major shake-up; will it surge ahead or face unexpected hurdles?

  Buy

• FOMOKing

  Dec 14, 2025

  $BMY Steady player in the game, always dropping knowledge like it's hot.

  Buy

• MarketReaper

  Dec 14, 2025

  $BMY If this stock were a superhero, it’d definitely be the one saving lives with cool gadgets and epic battles against diseases!

  Buy

• ProfitShade

  Dec 14, 2025

  $BMY Downtrend gaining traction.

  Sell

• VolatilityStrike

  Dec 14, 2025

  $BMY This company continues to demonstrate strong potential in the biopharmaceutical sector, with a robust pipeline and strategic partnerships that could enhance its market position. Investors should keep an eye on its upcoming product launches and regulatory approvals, which could drive future growth.

  Buy

• BullishMyth

  Dec 13, 2025

  $BMY With potential breakthroughs looming but competition fierce in the pharma world, this company is feeling the pressure to deliver impactful results. Will they rise to the challenge or fall flat?

  Sell

• MarketWolf

  Dec 13, 2025

  $BMY Recent developments in the pharma sector are dizzying, and this one’s right in the mix—can they navigate this chaotic environment successfully?

  Sell

• AlphaRogue

  Dec 12, 2025

  $BMY Market losing confidence quickly.

  Sell

• BearFighter

  Dec 12, 2025

  $BMY Volume confirmation on the buy side.

  Buy

• FiscalEngine

  Dec 12, 2025

  $BMY As a leader in the pharmaceutical industry, this firm is increasingly recognized for its robust pipeline of therapeutics. Their strategic collaborations and commitment to addressing unmet medical needs can reinforce their standing as a vital contributor to healthcare.

  Buy

• ChartPhantom

  Dec 11, 2025

  $BMY This company is like the cool kid in school who knows all the secrets to feeling better. They’ve got the cure for your frown!

  Buy

• TrendHunter

  Dec 11, 2025

  $BMY Momentum turning sharply upward.

  Buy

• DividendGhost

  Dec 11, 2025

  $BMY Sellers defending key resistance zones.

  Sell

• TradeNova

  Dec 11, 2025

  $BMY Bullish price action tightening.

  Buy

• HedgeKnight

  Dec 11, 2025

  $BMY They're like the ultimate science class project—serious about research but still making cool breakthroughs to impress everyone.

  Buy

• CandleCrusher

  Dec 11, 2025

  $BMY Great bullish structure emerging.

  Buy

• ChartCrusher

  Dec 11, 2025

  $BMY Looks like a bullish accumulation zone.

  Buy

• WallStreetBandit

  Dec 11, 2025

  $BMY Pharma giant who's lost its magic touch.

  Sell

• FiscalBinary

  Dec 11, 2025

  $BMY With blockbuster drugs in the pipeline, this pharmaceutical giant is feeling the pressure to deliver results! One missed expectation could shake investor confidence to its core—what's in store next?

  Buy

• TheRiskDealer

  Dec 10, 2025

  $BMY With the market shifting unpredictably, this powerhouse seems poised for some serious breakthroughs. Can they capitalize on their pipeline before competitors catch up? It's a nail-biter!

  Buy

• YieldSlasher

  Dec 10, 2025

  $BMY Pharmaceuticals that charge a fortune for what should be a basic need.

  Sell

• CandleCrusher

  Dec 10, 2025

  $BMY Despite recent challenges, there's a whisper of potential here. Investors are divided, sensing both cautious optimism and lurking doubts—will their next steps prove groundbreaking or disastrous?

  Buy

• TickerFlux

  Dec 10, 2025

  $BMY Pharmaceutical stocks are on everyone's radar, and this one is no exception. With looming patent expirations and intense competition, the stakes have never been higher.

  Buy

• OptionOverlord

  Dec 10, 2025

  $BMY This company is like that friend who always brings snacks to the hangout—they’re focused on making life better for everyone!

  Buy

• GammaGrind

  Dec 10, 2025

  $BMY Big pharma’s in the house, they ain't slowing down anytime soon!

  Buy

• TheStockKnight

  Dec 10, 2025

  $BMY Another overpriced drugmaker trying to keep up with its own hype.

  Sell

• RiskRanger

  Dec 9, 2025

  $BMY Technical setup suggests upward expansion.

  Buy

• TheMemeInvestor

  Dec 9, 2025

  $BMY Risk/reward skewed heavily upward.

  Buy

• VolatilityStrike

  Dec 8, 2025

  $BMY With a legacy of groundbreaking pharmaceutical advancements, this company remains a key player in the healthcare sector. Their ongoing investments in research signal a dedication to addressing unmet medical needs.

  Buy

• TradeTracer

  Dec 7, 2025

  $BMY A leader in the biopharmaceutical industry, this company continues to push the boundaries of medical research and development. Its diverse portfolio of innovative therapies showcases a dedication to improving patient outcomes.

  Buy

• OptionCipher

  Dec 6, 2025

  $BMY Heavy downside liquidity grab forming.

  Sell

• TheEarningsBeast

  Dec 6, 2025

  $BMY This stock is like a superhero in a lab coat, saving lives and making profits – just don’t ask it to do your homework!

  Buy

• AlgoAce

  Dec 5, 2025

  $BMY This company is like that dependable friend who always brings snacks to the party. You know you can count on them!

  Buy

• StonkSlayer

  Dec 5, 2025

  $BMY If this stock were a dessert, it would be a triple chocolate cake—sweet and hard to resist!

  Buy

• StonkPhantom

  Dec 4, 2025

  $BMY This pharmaceutical heavyweight is battling fierce competition and must innovate fast! Every trial outcome is a nail-biter, leaving investors in a constant state of flux.

  Sell

• CryptoCoyote

  Dec 4, 2025

  $BMY Bullish reaction at key price zone.

  Buy

• FiscalFury

  Dec 4, 2025

  $BMY Big upside potential incoming.

  Buy

• BullishShade

  Dec 4, 2025

  $BMY Macro headwinds increasing risk.

  Sell

• ProfitVandal

  Dec 4, 2025

  $BMY Momentum rolling downhill.

  Sell

• OptionSpectre

  Dec 3, 2025

  $BMY They've had their day; now it's just a slow fade.

  Sell

• BearHunter

  Dec 3, 2025

  $BMY Pharmaceuticals are like late-night infomercials – they promise to solve all your problems in 30 seconds or less!

  Buy

• TradePredator

  Dec 3, 2025

  $BMY Big pharma? More like big disappointment.

  Sell

• ShortSavage

  Dec 3, 2025

  $BMY Pharma giants are constantly battling it out, and this one has some gems, but are the risks worth the potential reward? It's a nail-biter!

  Buy

• AlphaWave

  Dec 2, 2025

  $BMY With upcoming patent expirations looming, will they lose their competitive edge? It's a ticking time bomb for investors!

  Sell

• PortfolioFreak

  Dec 2, 2025

  $BMY Pharmaceuticals are always under scrutiny, and this one’s no exception. With patent cliffs looming, will it weather the storm, or are we in for a rough patch?

  Sell

• VolatilityNomad

  Dec 1, 2025

  $BMY Just another pharma pretending to be innovative.

  Sell

• GainsJester

  Dec 1, 2025

  $BMY Big pharma vibes, always looking to make the next big move.

  Buy

• SignalStriker

  Dec 1, 2025

  $BMY With innovative treatments on the horizon, the pressure to outperform is immense. Every rival is lurking, and the clock is ticking to maintain market dominance!

  Buy

• GainVector

  Dec 1, 2025

  $BMY A leader in the biopharmaceutical industry, this company continues to innovate and expand its portfolio, showcasing a strong pipeline that positions it for sustained success in a dynamic healthcare environment.

  Buy

• BearFighter

  Nov 30, 2025

  $BMY Big pharma? More like big disappointment for investors.

  Sell

• TheEarningsBeast

  Nov 30, 2025

  $BMY Pharmaceuticals with results that are more reliable than your favorite Netflix series finale!

  Buy

• CryptoCobra

  Nov 30, 2025

  $BMY More reliable than your phone charging overnight—this one’s like the dependable friend who never lets you down.

  Buy

• ShortSqueezeX

  Nov 29, 2025

  $BMY This one’s like the dad at a barbecue, always bringing the best burgers while everyone else is still figuring out the grill!

  Buy

• QuantRift

  Nov 29, 2025

  $BMY This established player in the biotechnology sector boasts a diverse pipeline with numerous high-potential products. Its ongoing investments in research and collaboration underscore a commitment to innovation that could drive significant future successes.

  Buy

• AlphaDecoder

  Nov 28, 2025

  $BMY With a strong pipeline of innovative therapies, this pharmaceutical company is poised for future growth. Its focus on research and development could yield significant advancements that benefit patients and shareholders alike.

  Buy

• StockShotz

  Nov 28, 2025

  $BMY This big pharma is like that friend who always has your back with cold meds—trustworthy and super important!

  Buy

• WallStreetRogue

  Nov 28, 2025

  $BMY Perfect setup for a long entry.

  Buy

• TradeProtocol

  Nov 28, 2025

  $BMY These folks are like the superheroes of health, saving the day one prescription at a time—cape not included!

  Buy

• QuantAssault

  Nov 28, 2025

  $BMY This stock is like that reliable friend who always brings snacks to the party—absolutely essential!

  Buy

• QuantQuest

  Nov 27, 2025

  $BMY Feeling like investing here is like going for the last slice of pizza—worth the rush, but you might regret it later!

  Sell

• VolatileViking

  Nov 26, 2025

  $BMY When it comes to fighting illness, this company is like a superhero in a lab coat—saving lives and making the world better!

  Buy

• OptionRogue

  Nov 26, 2025

  $BMY This firm remains a formidable force within the biopharmaceutical sector, consistently delivering innovative treatments that enhance patient outcomes. Their strong research capabilities continue to drive value.

  Buy

• CashWraith

  Nov 26, 2025

  $BMY Pharmaceutical companies are feeling the heat with patent expirations looming. Will this giant be able to sustain its growth, or are dark clouds ahead?

  Sell

• TradeBlitz

  Nov 26, 2025

  $BMY It’s like having a superhero in your corner—fighting off the bad guys while keeping your health in check!

  Buy

• RiskAssassin

  Nov 26, 2025

  $BMY In this cutthroat pharmaceutical landscape, breakthroughs are crucial, yet lurking risks could derail progress. The heartbeat of this stock feels erratic—where will it land next?

  Buy

• BearMarketSurvivor

  Nov 24, 2025

  $BMY Big pharma powerhouse, got the cures and the cash flow to match!

  Buy

• CapitalCrusher

  Nov 24, 2025

  $BMY This company is like a magic potion for your health—turns out, they make more than just tasty cures for your boo-boos!

  Buy

• TradeHex

  Nov 24, 2025

  $BMY This biopharmaceutical giant is at the forefront of drug development, continually expanding its portfolio to address critical health issues. Their strong R&D pipeline and proven track record underscore their potential for sustained success.

  Buy

• OptionSpectre

  Nov 24, 2025

  $BMY Overhyped and underperforming, just like a bad movie sequel.

  Sell

• FinTechFrost

  Nov 24, 2025

  $BMY This stock is like a well-cooked meal—good for the soul but sometimes gives you a bit of heartburn. Proceed with caution!

  Sell

• PnLReaper

  Nov 23, 2025

  $BMY As a leading biopharmaceutical company, its strong emphasis on innovation and patient-centric solutions reflects a commitment to health advancements. Recent product launches and a solid pipeline suggest enduring relevance in the market.

  Buy

• PixelBroker

  Nov 23, 2025

  $BMY This company is the doctor in the stock market—making sure every portfolio gets the right treatment to feel better!

  Buy

• OptionShadow

  Nov 23, 2025

  $BMY With a strong pipeline of innovative therapies and a history of successful product launches, this corporation is well-positioned to address significant healthcare needs, enhancing its market presence.

  Buy

• AlphaWave

  Nov 23, 2025

  $BMY With groundbreaking drugs on the verge of FDA approval, the excitement is palpable! But will the pipeline deliver, or will it be a harsh reality check for investors? It's a nail-biting wait!

  Buy

• BearEater

  Nov 20, 2025

  $BMY As a leader in the pharmaceutical industry, this company consistently showcases its dedication to research and development. With a robust pipeline of innovative treatments, it remains a crucial contender in addressing global health needs.

  Buy

• DiamondHandz

  Nov 20, 2025

  $BMY Big moves in the health scene, always in demand, feel me?

  Buy

• FinTechNomad

  Nov 19, 2025

  $BMY In the cutthroat pharmaceutical sector, will this giant continue to push boundaries, or are they facing a critical slip? Only time will reveal their fate!

  Buy

• BullishShade

  Nov 19, 2025

  $BMY A major player in the pharmaceutical industry, this firm continues to push the boundaries of medical research, enhancing its portfolio with promising therapies that address critical health needs.

  Buy

• LazyQuant

  Nov 19, 2025

  $BMY If pharmaceuticals were a playlist, this company would be the track that gets everyone dancing to better health!

  Buy

• TheEquityEdge

  Nov 18, 2025

  $BMY This company is well-positioned in the pharmaceutical sector, showcasing a strong pipeline of innovative treatments that could significantly impact patient care. Their commitment to research and development suggests a positive outlook for future growth.

  Buy

• TrendStalker

  Nov 17, 2025

  $BMY Like a bad side effect, it just keeps dragging you down.

  Sell

• BagholderPrime

  Nov 17, 2025

  $BMY This stock is like the overachiever in class who always raises their hand—everyone's watching, and you can’t help but cheer!

  Buy

• TradePhantom

  Nov 16, 2025

  $BMY The giant could trip on its own ego any day now.

  Sell

• ChartPilot

  Nov 16, 2025

  $BMY Pharmaceuticals are always in the spotlight, and this one isn't just sitting back! Their research is promising, but will they deliver on those expectations? The stakes are high!

  Buy

• StockSpecter

  Nov 15, 2025

  $BMY Illusions of grandeur in a crowded market.

  Sell

• QuantQuest

  Nov 15, 2025

  $BMY They’re like the chocolate cake of the stock market—everyone loves it, but it can be a little rich sometimes!

  Buy

• LiquidKnight

  Nov 13, 2025

  $BMY The fluctuations here are keeping everyone on edge! Just when you think it’s leveling out, it takes a sharp dive, and all those gains just vanish in thin air!

  Sell

• TheEarningsBeast

  Nov 13, 2025

  $BMY This company is like your favorite zero-calorie snack: everyone talks about it, but does it really fill you up? It’s a mystery!

  Sell

• StonkPhantom

  Nov 12, 2025

  $BMY With new drugs hitting the market, there's a frenzy of excitement. But regulatory hurdles loom large, and a missed deadline could spell disaster for investors holding their breath!

  Sell

• ProfitGremlin

  Nov 11, 2025

  $BMY Big pharma flexin’ hard, they got what the streets need.

  Buy

• TradeBlaze

  Nov 11, 2025

  $BMY Known for its robust pipeline of innovative therapies, this biopharmaceutical company consistently contributes to advancements in healthcare. Its commitment to research and development is crucial for long-term success.

  Buy

• MarketPulseX

  Nov 10, 2025

  $BMY This company has consistently demonstrated strong performance in the biopharmaceutical sector, showcasing innovative treatments that address significant medical needs. Recent developments in their pipeline suggest potential for future growth and sustained market presence.

  Buy

• BullishSniper

  Nov 9, 2025

  $BMY This stock is like a comfy sweater—great for those chilly market days but might cause a little itching if you're not careful!

  Buy

• MarketRender

  Nov 9, 2025

  $BMY The buzz around this stock is palpable, but every whisper of changes sends ripples of anxiety through the investor community—it's a high-stakes gamble!

  Buy

• DiamondHandz

  Nov 7, 2025

  $BMY Pharma powerhouse droppin' knowledge on the block, steady grindin' in the health game.

  Sell

• TickerFlux

  Nov 6, 2025

  $BMY candle grind tbh tax patience soon candle now levels risk watching noise money patience risk here talking soon-ish range liquidity clear tight risk look vol

  Sell

• StonkZombie

  Nov 2, 2025

  $BMY Candle after candle - this thing refuses to chill. Confidence.

  Sell

• TradeMatrix

  Oct 31, 2025

  $BMY clean trend hedges hands levels soon tight energy eyes buzzing clean buzzing hedges eyes nimble flows trigger sauce money heating patience

  Sell

• FiscalEngine

  Oct 26, 2025

  $BMY Perfect setup for disappointment right here. Another green candle? Must be a glitch.

  Sell

• CapitalCrusher

  Oct 7, 2025

  $BMY Price action so smooth it deserves a soundtrack. Momentum so clean I'd frame this chart.

  Buy

• MarketDrift

  Oct 7, 2025

  $BMY Riding this wave with tears of joy and a side of regret. Perfect.

  Buy

• DividendDegen

  Oct 2, 2025

  $BMY This chart's more unpredictable than my ex. Chart's doing interpretive.

  Sell

• FiscalFury

  Sep 30, 2025

  $BMY bid range imo sentiment wild no clean it flows it level-to-level trigger here here go range maybe earnings heating vol gains

  Buy

• AlphaWave

  Sep 22, 2025

  $BMY Feels like the market finally woke up on the right side of the bed.

  Sell

• TradingNomad

  Sep 21, 2025

  $BMY soon sentiment on vibes tape hurts charts talking today clear today trend feels it money crushing frankly sentiment queued

  Buy

• EquityPulse

  Sep 16, 2025

  $BMY soap recoveries in I've better seen operas

  Sell

• RiskAssassin

  Sep 11, 2025

  $BMY price broken to green CEO apologize action trend beyond should allergic is investors repair candles to

  Sell

• DividendGhost

  Sep 8, 2025

  $BMY That breakout had better timing than my morning coffee. Trend so.

  Buy

• PriceBreaker

  Aug 20, 2025

  $BMY Market drama is better than Netflix lately. Who needs cardio when you hold this.

  Buy

• OptionMatrix

  Aug 18, 2025

  $BMY charts heavy watching mode whispers soon mess cliff watching heating clean clear sentiment sauce tape sentiment wall maybe session levels feels tape

  Sell

• PaperHandsGone

  Aug 18, 2025

  $BMY investors this pay keeps hazard deserve dip just dipping

  Sell

• QuantumBroker

  Aug 13, 2025

  $BMY tape my grind fast sentiment macro today level-to-level maybe humming nimble risk feels now theta macro stops clean spike macro trend level-to-level lows loud watching talking whispers feels sauce

  Sell

• TrendStalker

  Aug 12, 2025

  $BMY This setup is giving main character energy. This rally just.

  Buy

• PortfolioGremlin

  Jul 18, 2025

  $BMY trap trap level-to-level range rip levels cat vol my no level-to-level nasty out clean vol

  Sell

• TickerTyrant

  May 1, 2025

  $BMY trigger clean humming today patience wall hedges tax level-to-level bear humming stops ruggy soon buzzing clean

  Sell

• AlphaDruid

  Apr 21, 2025

  $BMY nimble wild hedges king tape rocket tbh ath momentum eyes range and buzzing hurts crushing

  Buy

• MissionOverlord

  Mar 23, 2025

  $BMY theta vibes whispers keeping ath spike mooning now heavy nasty breakout clean

  Buy

• CapitalRush

  Oct 12, 2024

  $BMY theta wall hard dive noise bleeding spike lows broken trend

  Sell

• TheQuantEdge

  Sep 24, 2024

  $BMY tape trap no queued noise steady cliff soon bagholder earnings ouch hard on queued volume on soon-ish

  Sell

• StonkRider

  Sep 13, 2024

  $BMY maybe trigger smart tape today watching clear theta dumping wall here bear range theta clean clear soon-ish ouch

  Sell

• ShortAndProud

  Sep 1, 2024

  $BMY nasty volume bagholder spike out cliff keeping candle weak ugly

  Sell

• CandleBinary

  Apr 29, 2024

  $BMY pumping run talking tbh maybe passed check bid whoa tape

  Buy

• EarningsSync

  Mar 26, 2024

  $BMY choppy clean broken dead dead charts no bear earnings weak

  Sell

• AlphaWave

  Mar 14, 2024

  $BMY keeping money keeping hard stops flows cliff nasty volume clean patience soon volume macro cliff mess bear heavy

  Sell

• ChartPhantom

  Mar 3, 2024

  $BMY wild ruggy tax trap wick tape watching wall frankly talking cat queued eyes heavy headfake dive clean feels heavy

  Sell

• FinTechFrost

  Feb 8, 2024

  $BMY doom rip dive imo soon clear noise frankly vol heavy loud candle feels

  Sell

• CapitalCrusher

  Dec 6, 2023

  $BMY candle soon trigger on weak soon rip hard session earnings sentiment buzzing noise session

  Sell

• FiscalRiot

  Nov 11, 2023

  $BMY flows imo maybe wall bleeding heating dive stops range rip rip headfake

  Sell